LSD1 was initially reported to act as an AR co-activator via demethylation of methylated H3K9 residue, along with upregulated expression of LSD1 in malignant prostate tumors (Metzger et al., 2005). This evidence concerns the gene KDM1A and Familial prostate cancer.